JP2003510328A - アゼピノインドール誘導体、その製法ならびに使用 - Google Patents

アゼピノインドール誘導体、その製法ならびに使用

Info

Publication number
JP2003510328A
JP2003510328A JP2001526542A JP2001526542A JP2003510328A JP 2003510328 A JP2003510328 A JP 2003510328A JP 2001526542 A JP2001526542 A JP 2001526542A JP 2001526542 A JP2001526542 A JP 2001526542A JP 2003510328 A JP2003510328 A JP 2003510328A
Authority
JP
Japan
Prior art keywords
alkyl
formula
hydrogen
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001526542A
Other languages
English (en)
Japanese (ja)
Inventor
ルービッシュ ヴィルフリート
コック ミヒャエル
ヘーガー トーマス
シュルト ザビーネ
グランデル ローラント
ミュラー ラインホールト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/de
Priority claimed from DE10039610A external-priority patent/DE10039610A1/de
Application filed by BASF SE filed Critical BASF SE
Publication of JP2003510328A publication Critical patent/JP2003510328A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
JP2001526542A 1999-09-28 2000-09-15 アゼピノインドール誘導体、その製法ならびに使用 Pending JP2003510328A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (de) 1999-09-28 1999-09-28 Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE19946289.5 1999-09-28
DE10039610A DE10039610A1 (de) 2000-08-09 2000-08-09 Azepinoindol-Derivate, deren Herstellung und Anwendung
DE10039610.0 2000-08-09
PCT/EP2000/009024 WO2001023390A2 (de) 1999-09-28 2000-09-15 Azepinoindol-derivate, deren herstellung und anwendung

Publications (1)

Publication Number Publication Date
JP2003510328A true JP2003510328A (ja) 2003-03-18

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001526542A Pending JP2003510328A (ja) 1999-09-28 2000-09-15 アゼピノインドール誘導体、その製法ならびに使用

Country Status (17)

Country Link
EP (1) EP1183259A2 (de)
JP (1) JP2003510328A (de)
KR (1) KR20010087401A (de)
CN (1) CN1374961A (de)
AU (1) AU1271201A (de)
BG (1) BG105650A (de)
BR (1) BR0007174A (de)
CA (1) CA2352194A1 (de)
CZ (1) CZ20012373A3 (de)
HK (1) HK1048999A1 (de)
HU (1) HUP0104917A3 (de)
IL (1) IL143349A0 (de)
NO (1) NO20012567L (de)
PL (1) PL347885A1 (de)
SK (1) SK8842001A3 (de)
TR (1) TR200101499T1 (de)
WO (1) WO2001023390A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513475A (ja) * 2008-03-14 2011-04-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）の阻害剤としての三環式誘導体
JP2020521762A (ja) * 2017-05-24 2020-07-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア イメージング及び放射線療法のための放射標識された蛍光性ｐａｒｐ阻害剤

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140936B1 (de) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclische inhibitoren von poly(adp-ribose) polymerasen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1339402B1 (de) 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
ATE546539T1 (de) 2002-07-26 2012-03-15 Basf Plant Science Gmbh Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
ATE541043T1 (de) 2005-03-08 2012-01-15 Basf Plant Science Gmbh Expressionsverstärkende intron-sequenz
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
JP5922029B2 (ja) 2009-11-27 2016-05-24 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー キメラエンドヌクレアーゼおよびその使用
AU2010325549B2 (en) 2009-11-27 2017-04-20 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
KR101896567B1 (ko) 2015-07-23 2018-09-07 인스티튜트 큐리 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
EP3765613A1 (de) 2018-03-13 2021-01-20 Onxeo Dbait-molekül gegen erworbene resistenz in der behandlung von krebs
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20210125024A (ko) * 2019-02-02 2021-10-15 치아타이 티안큉 파마수티컬 그룹 주식회사 Parp 억제제로서의 인돌로 헵타밀 옥심 유사체
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021318572A1 (en) * 2020-07-31 2023-02-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
EP1140936B1 (de) * 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclische inhibitoren von poly(adp-ribose) polymerasen
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513475A (ja) * 2008-03-14 2011-04-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）の阻害剤としての三環式誘導体
JP2020521762A (ja) * 2017-05-24 2020-07-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア イメージング及び放射線療法のための放射標識された蛍光性ｐａｒｐ阻害剤
JP7264489B2 (ja) 2017-05-24 2023-04-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア イメージング及び放射線療法のための放射標識された蛍光性ｐａｒｐ阻害剤

Also Published As

Publication number Publication date
HK1048999A1 (zh) 2003-04-25
HUP0104917A3 (en) 2002-12-28
CN1374961A (zh) 2002-10-16
SK8842001A3 (en) 2002-01-07
KR20010087401A (ko) 2001-09-15
IL143349A0 (en) 2002-04-21
NO20012567L (no) 2001-06-25
BR0007174A (pt) 2001-09-04
CA2352194A1 (en) 2001-04-05
TR200101499T1 (tr) 2002-09-23
WO2001023390A2 (de) 2001-04-05
WO2001023390A3 (de) 2001-12-27
BG105650A (en) 2002-02-28
HUP0104917A2 (hu) 2002-04-29
NO20012567D0 (no) 2001-05-25
EP1183259A2 (de) 2002-03-06
PL347885A1 (en) 2002-04-22
AU1271201A (en) 2001-04-30
CZ20012373A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
JP2003510328A (ja) アゼピノインドール誘導体、その製法ならびに使用
US7087637B2 (en) Substituted indoles which are PARP inhibitors
US7041675B2 (en) Heterocyclic compounds and their use as PARP inhibitors
KR100417779B1 (ko) 치환된 벤즈이미다졸 및 ｐａｒｐ 억제제로서 그의 용도
US6696437B1 (en) Heterocyclically substituted benzimidazoles, the production and application thereof
EP1222191B1 (de) Benzodiazepin-derivate, deren herstellung und anwendung
JP2002529537A (ja) ２−フェニルベンズイミダゾールおよび２−フェニルインドール、その製造方法ならびに使用
KR20020000642A (ko) 프탈라진 유도체의 용도
BG65513B1 (bg) Циклоалкил-заместени бензимидазоли, лекарства, които ги съдържат, и използването им
JP4308017B2 (ja) ジベンゾジアゼピン誘導体、その製造及び使用
MXPA01005199A (en) Azepinoindole derivatives, the production and use thereof
WO2021104506A1 (zh) 环状砜类化合物及其制备方法、药物组合物和用途
DE10039610A1 (de) Azepinoindol-Derivate, deren Herstellung und Anwendung
MXPA01005197A (en) Substituted benzimidazoles and their use as parp inhibitors
MXPA01010673A (es) Benzimidazoles ciclo-alquil substituidos y su uso como inhibidores parp

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040213